Phase I/II study of Carfilzomib in combination with bendamustine and dexamethasone in patients with newly diagnosed multiple myeloma
Study for newly diagnosed patients of multiple myeloma with study drug (Carfilzomib)
Sponsor: Onyx Therapeutics Inc.
Enrolling: Male and Female Patients
IRB Number: AAAJ2359
U.S. Govt. ID: NCT02002598
Contact: Siyang Leng, MD: 646-317-4840 / sl4076@cumc.columbia.edu
Additional Study Information: This is a study of a study drug, Carfilzomib in combination with bendamustine and dexamethasone for subjects with newly diagnosed multiple myeloma. The purpose of this study is to find the highest tolerable dose of carfilzomib with the combination of bendamustine and dexamethasone. The response rate and the safety of this drug combination will also be studied.
This study is closed
Investigator
Suzanne Lentzsch, MD
Do You Qualify?
Do you have multiple myeloma? Yes No
Have you previously had chemotherapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Siyang Leng, MD
sl4076@cumc.columbia.edu
646-317-4840
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE